EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacometabolomics in TB meningitis—Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid

Jeffrey M Collins iD, Maia Kipiani, Yutong Jin iD, Ashish A Sharma, Jeffrey A Tomalka, Teona Avaliani, Mariam Gujabidze, Tinatin Bakuradze, Shorena Sabanadze, Zaza Avaliani, Henry M Blumberg, David Benkeser und 3 weitere

PLOS ONE · 03.03.2025 · 20 (3) · e0315999

DOI: 10.1371/journal.pone.0315999 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 03.03.2025. Verfasst von Jeffrey M Collins und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America. Hauptthemen laut MEDLINE: Tuberculosis, Meningeal, Antitubercular Agents, Metabolomics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, FIC NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poor penetration of many anti-tuberculosis (TB) antibiotics into the central nervous system (CNS) is thought to be a major driver of morbidity and mortality in TB meningitis (TBM). While the amount of a particular drug that crosses into the cerebrospinal fluid (CSF) varies from person to person, little is known about the host factors associated with interindividual differences in CSF concentrations of anti-TB drugs. In patients diagnosed with TBM from the country of Georgia (n = 17), we investigate the association between CSF concentrations of anti-TB antibiotics and multiple host factors including serum drug concentrations and CSF concentrations of metabolites and cytokines. We found > 2-fold differences in CSF concentrations of anti-TB antibiotics from person to person for all drugs tested including cycloserine, ethambutol, imipenem, isoniazid, levofloxacin, linezolid, moxifloxacin, pyrazinamide, and rifampin. While serum drug concentrations explained over 30% of the variation in CSF drug concentrations for cycloserine, isoniazid, linezolid, and pyrazinamide (adjusted R 2 ≥ 0.3, p < 0.001 for all), there was no significant association between serum concentrations of imipenem and ethambutol and their respective CSF concentrations. CSF concentrations of carnitines were significantly associated with concentrations of ethambutol and imipenem (q < 0.05), and imipenem was the only antibiotic significantly associated with CSF cytokine concentrations. These results indicate that there is high interindividual variability in CSF drug concentrations in patients treated for TBM, which is only partially explained by differences in serum drug concentrations. With the exception of imipenem, there was no association between CSF drug concentrations and concentrations of cytokines and chemokines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, MeningealAntitubercular AgentsMetabolomicsHumansMaleFemaleAdultMiddle AgedIsoniazidCytokinesCycloserineYoung AdultAgedEthambutol

Substanzen

Antitubercular AgentsIsoniazidCytokinesCycloserineEthambutol

Autor:innen und Institutionen

  • Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
  • The University of Georgia, Tbilisi, Georgia.
  • David Tvildiani Medical University, The University of Georgia, Tbilisi, Georgia.
  • Department of Biostatistics, Rollins School of Public Health of Emory University, Atlanta, Georgia, United States of America.
  • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.

ORCID-Profile: Jeffrey M Collins, Yutong Jin, Charles Peloquin, Russell R Kempker

Förderung

  • NIAID NIH HHS
  • FIC NIH HHS
  • NCATS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Center for Advancing Translational Sciences
  • Fogarty International Center

Zitieren

APA

Collins, J. M., Kipiani, M., Jin, Y., Sharma, A. A., Tomalka, J. A., Avaliani, T., Gujabidze, M., Bakuradze, T., Sabanadze, S., Avaliani, Z., Blumberg, H. M., Benkeser, D., Jones, D. P., Peloquin, C., & Kempker, R. R. (2025). Pharmacometabolomics in TB meningitis—Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid. PLOS ONE, 20(3), e0315999. https://doi.org/10.1371/journal.pone.0315999

Vancouver

Collins JM, Kipiani M, Jin Y, Sharma AA, Tomalka JA, Avaliani T, et al. Pharmacometabolomics in TB meningitis—Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid. PLOS ONE. 2025;20(3):e0315999. doi:10.1371/journal.pone.0315999

BibTeX
@article{Collins2025,
  author = {Collins, Jeffrey M and Kipiani, Maia and Jin, Yutong and Sharma, Ashish A and Tomalka, Jeffrey A and Avaliani, Teona and Gujabidze, Mariam and Bakuradze, Tinatin and Sabanadze, Shorena and Avaliani, Zaza and Blumberg, Henry M and Benkeser, David and Jones, Dean P and Peloquin, Charles and Kempker, Russell R},
  title = {Pharmacometabolomics in TB meningitis—Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {3},
  pages = {e0315999},
  doi = {10.1371/journal.pone.0315999}
}
Kostenlos starten →